JP2018532692A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018532692A5 JP2018532692A5 JP2018505625A JP2018505625A JP2018532692A5 JP 2018532692 A5 JP2018532692 A5 JP 2018532692A5 JP 2018505625 A JP2018505625 A JP 2018505625A JP 2018505625 A JP2018505625 A JP 2018505625A JP 2018532692 A5 JP2018532692 A5 JP 2018532692A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally substituted
- disease
- group
- groups
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 description 43
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 28
- 201000010099 disease Diseases 0.000 description 24
- 150000001875 compounds Chemical class 0.000 description 21
- 208000017442 Retinal disease Diseases 0.000 description 19
- 206010038923 Retinopathy Diseases 0.000 description 17
- 125000000753 cycloalkyl group Chemical group 0.000 description 16
- 125000000623 heterocyclic group Chemical group 0.000 description 15
- 150000002367 halogens Chemical class 0.000 description 14
- 125000003118 aryl group Chemical group 0.000 description 13
- 102100021145 fMet-Leu-Phe receptor Human genes 0.000 description 11
- 125000000392 cycloalkenyl group Chemical group 0.000 description 10
- 229910052736 halogen Inorganic materials 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 9
- 125000001188 haloalkyl group Chemical group 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 230000002207 retinal effect Effects 0.000 description 8
- 208000017520 skin disease Diseases 0.000 description 8
- 101000818546 Homo sapiens N-formyl peptide receptor 2 Proteins 0.000 description 7
- 101000818522 Homo sapiens fMet-Leu-Phe receptor Proteins 0.000 description 7
- 102100021126 N-formyl peptide receptor 2 Human genes 0.000 description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- 231100000241 scar Toxicity 0.000 description 7
- 201000004681 Psoriasis Diseases 0.000 description 6
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 6
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 6
- 230000008484 agonism Effects 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 239000000790 retinal pigment Substances 0.000 description 6
- 201000004624 Dermatitis Diseases 0.000 description 5
- 208000002780 macular degeneration Diseases 0.000 description 5
- 201000001441 melanoma Diseases 0.000 description 5
- 208000002874 Acne Vulgaris Diseases 0.000 description 4
- 206010004146 Basal cell carcinoma Diseases 0.000 description 4
- 206010012438 Dermatitis atopic Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 208000003351 Melanosis Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 4
- 206010051246 Photodermatosis Diseases 0.000 description 4
- 206010036229 Post inflammatory pigmentation change Diseases 0.000 description 4
- 206010072170 Skin wound Diseases 0.000 description 4
- 206010042496 Sunburn Diseases 0.000 description 4
- 206010000496 acne Diseases 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 201000008937 atopic dermatitis Diseases 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 101710108492 fMet-Leu-Phe receptor Proteins 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 206010023332 keratitis Diseases 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 230000008845 photoaging Effects 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 230000037390 scarring Effects 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 3
- 201000004384 Alopecia Diseases 0.000 description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- 208000031886 HIV Infections Diseases 0.000 description 3
- 208000037357 HIV infectious disease Diseases 0.000 description 3
- 206010020649 Hyperkeratosis Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000002260 Keloid Diseases 0.000 description 3
- 208000001126 Keratosis Diseases 0.000 description 3
- 208000012641 Pigmentation disease Diseases 0.000 description 3
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 3
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 3
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 3
- 125000003172 aldehyde group Chemical group 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 125000003368 amide group Chemical group 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 3
- 125000002843 carboxylic acid group Chemical group 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 125000004185 ester group Chemical group 0.000 description 3
- 125000001033 ether group Chemical group 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000001969 hypertrophic effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 3
- 210000001117 keloid Anatomy 0.000 description 3
- 125000000468 ketone group Chemical group 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 125000002560 nitrile group Chemical group 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphonic acid group Chemical group P(O)(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 3
- XNQULTQRGBXLIA-UHFFFAOYSA-O phosphonic anhydride Chemical compound O[P+](O)=O XNQULTQRGBXLIA-UHFFFAOYSA-O 0.000 description 3
- 230000008832 photodamage Effects 0.000 description 3
- 210000001927 retinal artery Anatomy 0.000 description 3
- 208000008742 seborrheic dermatitis Diseases 0.000 description 3
- 125000000565 sulfonamide group Chemical group 0.000 description 3
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 3
- 125000000542 sulfonic acid group Chemical group 0.000 description 3
- 150000003536 tetrazoles Chemical group 0.000 description 3
- 150000007970 thio esters Chemical group 0.000 description 3
- 125000000101 thioether group Chemical group 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- 229930192474 thiophene Natural products 0.000 description 3
- 150000003852 triazoles Chemical class 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 208000014882 Carotid artery disease Diseases 0.000 description 2
- 208000002691 Choroiditis Diseases 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 241000228402 Histoplasma Species 0.000 description 2
- 208000003971 Posterior uveitis Diseases 0.000 description 2
- 201000007737 Retinal degeneration Diseases 0.000 description 2
- 206010038848 Retinal detachment Diseases 0.000 description 2
- 241001303601 Rosacea Species 0.000 description 2
- 206010046914 Vaginal infection Diseases 0.000 description 2
- 201000008100 Vaginitis Diseases 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 208000037828 epithelial carcinoma Diseases 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000000414 obstructive effect Effects 0.000 description 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000004264 retinal detachment Effects 0.000 description 2
- 208000004644 retinal vein occlusion Diseases 0.000 description 2
- 201000004700 rosacea Diseases 0.000 description 2
- 230000037387 scars Effects 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 208000004142 Acute Retinal Necrosis Syndrome Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 201000007795 Bietti crystalline corneoretinal dystrophy Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010070957 Choroidal haemangioma Diseases 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 208000001351 Epiretinal Membrane Diseases 0.000 description 1
- 206010015943 Eye inflammation Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 208000021710 Hyperpigmentation disease Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010058558 Hypoperfusion Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000032578 Inherited retinal disease Diseases 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- 208000001344 Macular Edema Diseases 0.000 description 1
- 208000031471 Macular fibrosis Diseases 0.000 description 1
- 206010025415 Macular oedema Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- 208000001140 Night Blindness Diseases 0.000 description 1
- 206010069385 Ocular ischaemic syndrome Diseases 0.000 description 1
- 206010065700 Ocular sarcoidosis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000034247 Pattern dystrophy Diseases 0.000 description 1
- 206010064714 Radiation retinopathy Diseases 0.000 description 1
- 208000011131 Reticuloendothelial disease Diseases 0.000 description 1
- 201000007527 Retinal artery occlusion Diseases 0.000 description 1
- 208000032430 Retinal dystrophy Diseases 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 206010038915 Retinitis viral Diseases 0.000 description 1
- 208000005074 Retroviridae Infections Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
- -1 Thiaziazole Chemical compound 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 206010058990 Venous occlusion Diseases 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 208000010217 blepharitis Diseases 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 201000005849 central retinal artery occlusion Diseases 0.000 description 1
- 201000005667 central retinal vein occlusion Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 208000027129 choroid disease Diseases 0.000 description 1
- 230000009852 coagulant defect Effects 0.000 description 1
- 201000000159 corneal neovascularization Diseases 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 201000011190 diabetic macular edema Diseases 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 206010014801 endophthalmitis Diseases 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 208000011323 eye infectious disease Diseases 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 201000006321 fundus dystrophy Diseases 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000006589 gland dysfunction Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 208000034737 hemoglobinopathy Diseases 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 208000017532 inherited retinal dystrophy Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000035168 lymphangiogenesis Effects 0.000 description 1
- 201000010230 macular retinal edema Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000008940 ocular tuberculosis Diseases 0.000 description 1
- 208000008798 osteoma Diseases 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000006187 phenyl benzyl group Chemical group 0.000 description 1
- 230000000649 photocoagulation Effects 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 210000001957 retinal vein Anatomy 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021100178A JP2021178821A (ja) | 2015-08-05 | 2021-06-16 | ホルミルペプチド受容体１（ｆｐｒ１）選択的アゴニストとしてのフェニル尿素類似体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562201387P | 2015-08-05 | 2015-08-05 | |
| US62/201,387 | 2015-08-05 | ||
| PCT/US2016/045114 WO2017023907A1 (en) | 2015-08-05 | 2016-08-02 | Phenyl urea analogs as formyl peptide repceptor 1 (fpr1) selective agonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021100178A Division JP2021178821A (ja) | 2015-08-05 | 2021-06-16 | ホルミルペプチド受容体１（ｆｐｒ１）選択的アゴニストとしてのフェニル尿素類似体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018532692A JP2018532692A (ja) | 2018-11-08 |
| JP2018532692A5 true JP2018532692A5 (enExample) | 2021-03-25 |
| JP6900365B2 JP6900365B2 (ja) | 2021-07-07 |
Family
ID=56684759
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018505625A Expired - Fee Related JP6900365B2 (ja) | 2015-08-05 | 2016-08-02 | ホルミルペプチド受容体１（ｆｐｒ１）選択的アゴニストとしてのフェニル尿素類似体 |
| JP2021100178A Pending JP2021178821A (ja) | 2015-08-05 | 2021-06-16 | ホルミルペプチド受容体１（ｆｐｒ１）選択的アゴニストとしてのフェニル尿素類似体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021100178A Pending JP2021178821A (ja) | 2015-08-05 | 2021-06-16 | ホルミルペプチド受容体１（ｆｐｒ１）選択的アゴニストとしてのフェニル尿素類似体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20200079729A1 (enExample) |
| EP (1) | EP3331897B1 (enExample) |
| JP (2) | JP6900365B2 (enExample) |
| AU (2) | AU2016302146B2 (enExample) |
| CA (1) | CA2992662A1 (enExample) |
| TW (1) | TW201718473A (enExample) |
| WO (1) | WO2017023907A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| US12478503B2 (en) | 2009-05-18 | 2025-11-25 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
| TW201718473A (zh) * | 2015-08-05 | 2017-06-01 | 歐樂根公司 | 作為甲醯肽受體１（ｆｐｒ１）選擇性促效劑之苯基脲類似物 |
| ITUB20169937A1 (it) * | 2016-01-12 | 2017-07-12 | Medical And Biotechnological Services In Sigla M B S Srl | Formulazioni farmaceutiche e loro uso per il trattamento della retinite pigmentosa |
| WO2017172761A1 (en) | 2016-03-28 | 2017-10-05 | Allergan, Inc. | Phenyl urea derivatives as n-formyl peptide receptor modulators |
| CN109641857A (zh) | 2016-04-12 | 2019-04-16 | 阿勒根公司 | 作为n-甲酰基肽受体调节剂的苯基脲衍生物 |
| ES2943136T3 (es) * | 2018-09-27 | 2023-06-09 | Inst Nat Sante Rech Med | Polipéptido de TAFA4 para su uso para reducir la inflamación cutánea |
| GB202404002D0 (en) * | 2024-03-20 | 2024-05-01 | Univ Bristol | Antimicrobial compounds |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3387948B2 (ja) * | 1992-12-04 | 2003-03-17 | 富山化学工業株式会社 | 新規なフェニルアラニン誘導体またはその塩 |
| MX376348B (es) * | 2011-10-26 | 2025-03-07 | Allergan Inc | Derivados de amida de aminoacidos sustituidos con n-urea como moduladores de receptor de tipo peptido receptor de formilo-1 (fprl-1). |
| KR20140145203A (ko) * | 2012-04-16 | 2014-12-22 | 알러간, 인코포레이티드 | 포르밀 펩타이드 수용체 2 조절물질로서 (2-우레이도아세트아미도)알킬 유도체 |
| ES2708571T3 (es) * | 2013-07-16 | 2019-04-10 | Allergan Inc | Derivados de aminoácidos sustituidos con N-urea como moduladores del receptor de péptido formilado |
| TW201718473A (zh) * | 2015-08-05 | 2017-06-01 | 歐樂根公司 | 作為甲醯肽受體１（ｆｐｒ１）選擇性促效劑之苯基脲類似物 |
-
2016
- 2016-08-02 TW TW105124494A patent/TW201718473A/zh unknown
- 2016-08-02 US US15/746,918 patent/US20200079729A1/en not_active Abandoned
- 2016-08-02 JP JP2018505625A patent/JP6900365B2/ja not_active Expired - Fee Related
- 2016-08-02 EP EP16751427.2A patent/EP3331897B1/en not_active Not-in-force
- 2016-08-02 CA CA2992662A patent/CA2992662A1/en not_active Abandoned
- 2016-08-02 WO PCT/US2016/045114 patent/WO2017023907A1/en not_active Ceased
- 2016-08-02 AU AU2016302146A patent/AU2016302146B2/en not_active Ceased
-
2020
- 2020-12-24 AU AU2020294291A patent/AU2020294291A1/en not_active Abandoned
-
2021
- 2021-06-16 JP JP2021100178A patent/JP2021178821A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018532692A5 (enExample) | ||
| JP5917555B2 (ja) | ケモカイン受容体調節因子としてのリン酸誘導体 | |
| KR101982370B1 (ko) | N-포밀 펩타이드 수용체 유사-1(fprl-1) 수용체 조절제로서의 아릴 유레아 유도체 | |
| JP6900365B2 (ja) | ホルミルペプチド受容体１（ｆｐｒ１）選択的アゴニストとしてのフェニル尿素類似体 | |
| RU2688163C2 (ru) | Способы, соединения и композиции для лечения связанных с ангиотензином заболеваний | |
| JP2015520130A5 (enExample) | ||
| JP2006526581A5 (enExample) | ||
| JP2015520130A (ja) | ホルミルペプチド受容体２調節物質としての（２−ウレイドアセトアミド）アルキル誘導体 | |
| JP6653253B2 (ja) | ホルミルペプチド受容体モジュレーターとしてのｎ−尿素置換アミノ酸の誘導体 | |
| JP2002509543A (ja) | 緑内障の治療のための副作用のないプロスタグランジン誘導体 | |
| UA116622C2 (uk) | Похідні 4-прегенен-11ss-17-21-тріол-3,20-діону для лікування хвороб очей | |
| CA3029489A1 (en) | 1h-pyrazol-1-yl-thiazoles as inhibitors of lactate dehydrogenase and methods of use thereof | |
| KR20120075481A (ko) | 치료적 유용성을 갖는 수용체 조절제로서 쿠마린 화합물 | |
| US9345678B2 (en) | Prostanoid receptor agonist compounds and methods of use for same | |
| JP6496728B2 (ja) | ホルミルペプチド受容体の調節因子としてのカルバミン酸フェニル誘導体 | |
| KR20070034574A (ko) | 헤테로아릴 술폰 및 술폰아미드 및 이들의 치료상의 용도 | |
| TW202233575A (zh) | 用於治療與lpa受體活性相關的病狀的化合物及組合物 | |
| JP2001527073A (ja) | Ｎ−フェニルアミド誘導体およびｎ−ピリジルアミド誘導体、該化合物の製造方法ならびに該化合物を含む医薬組成物 | |
| CA2866078C (en) | Benzofuran-2-sulfonamide derivatives as chemokine receptor modulators | |
| US9670190B2 (en) | Pyridinyl and pyrimidinyl sulfonamide derivatives as chemokine receptor modulators | |
| JP7032323B2 (ja) | Ｎ－ホルミルペプチド受容体モジュレーターとしてのフェニル尿素誘導体 | |
| JP2019515901A (ja) | Ｎ−ホルミルペプチド受容体モジュレータとしてのフェニル尿素誘導体 | |
| KR20140048874A (ko) | 스핑고신-1 포스페이트 수용체 조절제로서의 페닐 이환식 메틸 아민 유도체 | |
| UA56205C2 (uk) | Похідні нітрометилтіобензолу як інгібітори альдегідредуктази, спосіб їх отримання (варіанти) та фармацевтична композиція | |
| US20150152080A1 (en) | Benzothiophene sulfonamides derivatives as chemokine receptor modulators |